Previous Pause Next
Home >> News Center >>
Clinical Trials
Pulmatrix to Present Data on PUR118 for Respiratory Diseases at European Respiratory Society Congress PDF Print E-mail
Friday, 23 September 2011 01:52

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that data from two preclinical studies of its inhaled clinical drug candidate, PUR118, will be presented at The European Respiratory Society Annual Congress (ERS 2011), being held September 24-28, 2011, in Amsterdam, Netherlands.

New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia PDF Print E-mail
Friday, 23 September 2011 01:49

Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September 21-24 in Washington, D.C. BZA/CE is being developed by Pfizer for the treatment of moderate-to-severe hot flashes, vulvar and vaginal atrophy and the prevention of osteoporosis in women following menopause.

ExAblate® Neuro has Been Used to treat 30 Patients with Chronic Neurological Disorders Such as Essential Tremor, Neuropathic Pain and Parkinson's Disease PDF Print E-mail
Thursday, 22 September 2011 00:09

InSightec Ltd., the global leader in MR guided Focused Ultrasound (MRgFUS) technology, announced today that  its investigational ExAblate® Neuro system has been used in clinical studies to treat 30 patients suffering from chronic neurological disorders.

Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza A PDF Print E-mail
Thursday, 22 September 2011 00:06

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-032, a broadly protective, fully human monoclonal antibody for the treatment of influenza A virus.

BIOTRONIK Announces Completion of Enrollment in the BIOLUX P-I Clinical Study Investigating Drug-eluting Balloon Therapy for Peripheral Artery Disease PDF Print E-mail
Wednesday, 21 September 2011 00:41

BIOTRONIK, a leading European manufacturer of therapy solutions for vascular intervention, announced the completion of enrollment in the BIOLUX P-I – a clinical study investigating the use of a drug-eluting balloon (DEB) catheter, a promising new approach to treating disease in the more challenging peripheral vascular anatomy.

TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients PDF Print E-mail
Wednesday, 21 September 2011 00:39
TheraVasc ( announced the successful completion of a Phase I clinical trial of a drug, TV1001, to diabetic patients.
Glycotope Enrolls First Patients In Phase I Trial With TrasGEX (TM), A Glycooptimized HER2 Biobetter Antibody PDF Print E-mail
Tuesday, 20 September 2011 00:45

Glycotope GmbH, a leading company in the field of glycomics, announced today the enrollment of the first patients in a phase I dose finding trial to evaluate safety and tolerability of TrasGEX™.

Neurocrine Biosciences Announces That VMAT 2 Program Begins Enrollment In Second Phase II Clinical Trial PDF Print E-mail
Tuesday, 20 September 2011 00:41
Neurocrine Biosciences, Inc. announced today that it has initiated a second Phase II clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854.
Generex Makes Podium Presentation Of Clinical Data On Generex Oral-lyn™ At European Association For The Study Of Diabetes Annual Meeting PDF Print E-mail
Monday, 19 September 2011 01:19
Generex Biotechnology Corporation (OTCBB: GNBT) announced that Dr. Nicola Napolii, from University Campus Bio-Medico in Rome, Italy, made a podium presentation of the clinical data on Generex Oral-lyn™ buccal insulin spray on September 14, 2011 at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.
BMS-790052 Plus Peginterferon Alfa and Ribavirin Demonstrated up to 83% Sustained Virologic Response 24 Weeks Post-Treatment (SVR24) in Phase II Study of Genotype 1 Hepatitis C Patients PDF Print E-mail
Monday, 19 September 2011 01:14

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase II clinical trial of 48 treatment-naive genotype 1 hepatitis C infected patients in which treatment with BMS-790052, an NS5A replication complex inhibitor, in combination with peginterferon alfa and ribavirin (pegIFNalfa/RBV) maintained undetectable viral load at 24 weeks post-treatment (SVR24) in 83% (60 mg), 83% (10 mg) and 42% (3 mg) of patients, compared with 25% of patients in the pegIFNalfa/RBV control group after 48 weeks of combination therapy.

ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe PDF Print E-mail
Friday, 23 September 2011 01:50

Advanced Cell Technology, Inc. (“ACT”);(OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin treating patients as part of a Phase 1/2 clinical trial for Stargardt’s Macular Dystrophy (SMD) using retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs).

Acetylon Pharmaceuticals Announces Initiation of Phase 1-2a Clinical Trial of ACY-1215 for Multiple Myeloma PDF Print E-mail
Friday, 23 September 2011 01:48

Acetylon Pharmaceuticals today announced the initiation of patient treatments in a three-part Phase 1-2a clinical trial of ACY-1215, an oral Class II histone deacetylase (HDAC) inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

Aradigm Presents Additional Analyses of the Clinical Results From ORBIT-1 and ORBIT-2 Trials of Inhaled Ciprofloxacin at the 2011 European Respiratory Society (ERS) Annual Congress PDF Print E-mail
Thursday, 22 September 2011 00:07

Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands.

ARIAD Announces Start of Enrollment in Phase 1/2 Clinical Trial of Oral AP26113, an Investigational Dual Inhibitor of ALK and EGFR in Patients with Lung Cancer PDF Print E-mail
Thursday, 22 September 2011 00:05

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the start of patient dosing in an international Phase 1/2 clinical trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) -- two clinically validated targets in non-small cell lung cancer (NSCLC).

SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center PDF Print E-mail
Wednesday, 21 September 2011 00:40
SanBio, Inc., a leader in cell therapies for regenerative medicine, has announced the site initiation and opening of a Phase 1/2a clinical trial testing a novel cell therapy product, SB623, in patients suffering from disability resulting from ischemic stroke.
First Patients Enrolled in the U.S. OPEN Clinical Trial of the FlexStent® Femoropopliteal SE Stent System PDF Print E-mail
Wednesday, 21 September 2011 00:38

Flexible Stenting Solutions Inc. announced today the successful treatment of the first two patients enrolled in the OPEN (Evaluation of Safety and Efficacy of the FlexStent® FemorOPopliteal Self-Expanding StENt System) clinical trial.

Gilead's Second Pivotal Phase 3 Clinical Study Of The Investigational Antiretroviral Quad Regimen Meets 48-Week Primary Objective PDF Print E-mail
Tuesday, 20 September 2011 00:43

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the second pivotal Phase 3 clinical trial (Study 103) of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada(R) (emtricitabine/tenofovir disoproxil fumarate) based on the proportion of subjects who achieved HIV RNA levels (viral load) of less than 50 copies/mL.

Attorney Robert Eglet Calls Plaintiffs To The Stand In 2nd Hepatitis C Trial In Clark County PDF Print E-mail
Tuesday, 20 September 2011 00:40

In the second trial following the largest notification by the Clark County Health Department that 50,000 residents of Nevada may be infected with hepatitis, plaintiff James Arnold took the stand today and described the first day he noticed his wife was sick following her colonoscopy treatment at the Endoscopy Center of Southern Nevada.

Novartis Study Showed ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With The Most Serious Form Of Childhood Arthritis PDF Print E-mail
Monday, 19 September 2011 01:18
Novartis announced positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease[3].
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment PDF Print E-mail
Monday, 19 September 2011 01:09
Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover.
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 7 of 122